| Primary | Number of Subjects With COVID-19 Symptoms at Day 3. | Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| Subject has at least one of the selected COVID-19 symptoms. | | | Subject has none of the selected COVID-19 symptoms. | |
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Mixed Models Analysis | Generalized linear mixed model (repeated binary logistic regression). | 0.3849 | | Odds Ratio (OR) | 1.49 | | | 2-Sided | 95 | 0.60 | 3.69 | | | | | Superiority | | |
|
| Primary | Number of Subjects With COVID-19 Symptoms at Day 7. | Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Primary | Number of Subjects With COVID-19 Symptoms at Day 10. | Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Primary | Number of Subjects With COVID-19 Symptoms at Day 14. | Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Mean Number of COVID-19 Symptoms at Day 3. | Mean number of COVID-19 symptoms (range 0-13) at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Mean | Standard Deviation | Symptoms | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Mean Number of COVID-19 Symptoms at Day 7. | Mean number of COVID-19 symptoms (range 0-13) at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Mean | Standard Deviation | Symptoms | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Mean Number of COVID-19 Symptoms at Day 10. | Mean number of COVID-19 symptoms (range 0-13) at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Mean | Standard Deviation | Symptoms | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Mean Number of COVID-19 Symptoms at Day 14. | Mean number of COVID-19 symptoms (range 0-13) at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Mean | Standard Deviation | Symptoms | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With Complete Disappearance of Any Symptom. | The descriptive statistics are the number of participants having complete disappearance of any symptom. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | From randomization to occurence of first event, assessed up to 14 days | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Cough Symptom. | Number of subjects with the cough symptom at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Cough Symptom. | Number of subjects with the cough symptom at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Cough Symptom. | Number of subjects with the cough symptom at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Cough Symptom. | Number of subjects with the cough symptom at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Fever. | Number of subjects with the presence of fever (temperature > 38 degrees) at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Fever. | Number of subjects with the presence of fever (temperature > 38 degrees) at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Fever. | Number of subjects with the presence of fever (temperature > 38 degrees) at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Fever. | Number of subjects with the presence of fever (temperature > 38 degrees) at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Shortness of Breath. | Number of subjects with the presence of shortness of breath at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Shortness of Breath. | Number of subjects with the presence of shortness of breath at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Shortness of Breath. | Number of subjects with the presence of shortness of breath at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Shortness of Breath. | Number of subjects with the presence of shortness of breath at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Anosmia. | Number of subjects with the presence of anosmia at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Anosmia. | Number of subjects with the presence of anosmia at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Anosmia. | Number of subjects with the presence of anosmia at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Anosmia. | Number of subjects with the presence of anosmia at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Feverish or Chills. | Number of subjects with the presence of feverish or chills at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Feverish or Chills. | Number of subjects with the presence of feverish or chills at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Feverish or Chills. | Number of subjects with the presence of feverish or chills at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Feverish or Chills. | Number of subjects with the presence of feverish or chills at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Sore Throat. | Number of subjects with the presence of sore throat at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Sore Throat. | Number of subjects with the presence of sore throat at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Sore Throat. | Number of subjects with the presence of sore throat at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Sore Throat. | Number of subjects with the presence of sore throat at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Runny Nose. | Number of subjects with the presence of runny nose at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Runny Nose. | Number of subjects with the presence of runny nose at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Runny Nose. | Number of subjects with the presence of runny nose at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Runny Nose. | Number of subjects with the presence of runny nose at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Nausea/Vomiting. | Number of subjects with the presence of nausea/vomiting at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Nausea/Vomiting. | Number of subjects with the presence of nausea/vomiting at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Nausea/Vomiting. | Number of subjects with the presence of nausea/vomiting at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Nausea/Vomiting. | Number of subjects with the presence of nausea/vomiting at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Headache. | Number of subjects with the presence of headache at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Headache. | Number of subjects with the presence of headache at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Headache. | Number of subjects with the presence of headache at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Headache. | Number of subjects with the presence of headache at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of General Weakness. | Number of subjects with the presence of general weakness at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of General Weakness. | Number of subjects with the presence of general weakness at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of General Weakness. | Number of subjects with the presence of general weakness at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of General Weakness. | Number of subjects with the presence of general weakness at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Pain. | Number of subjects with the presence of pain at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Pain. | Number of subjects with the presence of pain at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Pain. | Number of subjects with the presence of pain at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Pain. | Number of subjects with the presence of pain at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Irritability/Confusion. | Number of subjects with the presence of irritability/confusion at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Irritability/Confusion. | Number of subjects with the presence of irritability/confusion at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Irritability/Confusion. | Number of subjects with the presence of irritability/confusion at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Irritability/Confusion. | Number of subjects with the presence of irritability/confusion at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Diarrhea. | Number of subjects with the presence of diarrhea at day 3. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 3 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Diarrhea. | Number of subjects with the presence of diarrhea at day 7. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 7 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Diarrhea. | Number of subjects with the presence of diarrhea at day 10. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 10 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |
| Secondary | Number of Subjects With the Presence of Diarrhea. | Number of subjects with the presence of diarrhea at day 14. | Number of patients analysed differs from the number of patients assigned to the arm or comparison group as not all subjects replied to the questionnaire or follow-up call, whether a symptom occurred or not. | Posted | | Count of Participants | | Participants | | Day 14 | | | | ID | Title | Description |
|---|
| OG000 | Hesperidin 1000mg | Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. | | OG001 | Placebo 1000mg | Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water. |
| |